PMID- 23686375
OWN - NLM
STAT- MEDLINE
DCOM- 20140127
LR  - 20211021
IS  - 1573-904X (Electronic)
IS  - 0724-8741 (Linking)
VI  - 30
IP  - 8
DP  - 2013 Aug
TI  - Co-delivery of vascular endothelial growth factor and angiopoietin-1 using 
      injectable microsphere/hydrogel hybrid systems for therapeutic angiogenesis.
PG  - 2157-65
LID - 10.1007/s11095-013-1076-6 [doi]
AB  - PURPOSE: We hypothesized that combined delivery of vascular endothelial growth 
      factor (VEGF) and angiopoietin-1 (Ang-1) using microsphere/hydrogel hybrid 
      systems could enhance mature vessel formation compared with administration of 
      each factor alone. METHODS: Hybrid delivery systems composed of alginate 
      hydrogels and poly(D,L-lactic-co-glycolic acid) (PLGA) microspheres containing 
      angiogenic factors were prepared. The release behavior of angiogenic factors from 
      hybrid systems was monitored in vitro. The hybrid systems were injected into an 
      ischemic rodent model, and blood vessel formation at the ischemic site was 
      evaluated. RESULTS: The sustained release over 4 weeks of both VEGF and Ang-1 
      from hybrid systems was achieved in vitro. Co-delivery of VEGF and Ang-1 was 
      advantageous to retain muscle tissues and significantly induced vessel 
      enlargement at the ischemic site, compared to mice treated with either VEGF or 
      Ang-1 alone. CONCLUSIONS: Sustained and combined delivery of VEGF and Ang-1 
      significantly enhances vessel enlargement at the ischemic site, compared with 
      sustained delivery of either factor alone. Microsphere/hydrogel hybrid systems 
      may be a promising vehicle for delivery of multiple drugs for many therapeutic 
      applications.
FAU - Shin, Seung-Hwa
AU  - Shin SH
AD  - Department of Bioengineering, Hanyang University, Seoul 133-791, Republic of 
      Korea.
FAU - Lee, Jangwook
AU  - Lee J
FAU - Ahn, Dong-Gyun
AU  - Ahn DG
FAU - Lee, Kuen Yong
AU  - Lee KY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130518
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Alginates)
RN  - 0 (Angiopoietin-1)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Hexuronic Acids)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 8A5D83Q4RW (Glucuronic Acid)
SB  - IM
MH  - Alginates/chemistry
MH  - Angiopoietin-1/*administration & dosage
MH  - Animals
MH  - Cell Proliferation/drug effects
MH  - Delayed-Action Preparations/*chemistry
MH  - Female
MH  - Glucuronic Acid/chemistry
MH  - Hexuronic Acids/chemistry
MH  - Hindlimb/blood supply/drug effects
MH  - Hydrogel, Polyethylene Glycol Dimethacrylate/*chemistry
MH  - Lactic Acid/chemistry
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Microspheres
MH  - Neovascularization, Physiologic/drug effects
MH  - Polyglycolic Acid/chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Vascular Endothelial Growth Factor A/*administration & dosage
EDAT- 2013/05/21 06:00
MHDA- 2014/01/28 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/01/03 00:00 [received]
PHST- 2013/05/08 00:00 [accepted]
PHST- 2013/05/21 06:00 [entrez]
PHST- 2013/05/21 06:00 [pubmed]
PHST- 2014/01/28 06:00 [medline]
AID - 10.1007/s11095-013-1076-6 [doi]
PST - ppublish
SO  - Pharm Res. 2013 Aug;30(8):2157-65. doi: 10.1007/s11095-013-1076-6. Epub 2013 May 
      18.